CN112717119B - 一种西曲瑞克药物组合物及其制备方法 - Google Patents
一种西曲瑞克药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN112717119B CN112717119B CN202110113618.9A CN202110113618A CN112717119B CN 112717119 B CN112717119 B CN 112717119B CN 202110113618 A CN202110113618 A CN 202110113618A CN 112717119 B CN112717119 B CN 112717119B
- Authority
- CN
- China
- Prior art keywords
- cetrorelix
- hydrochloric acid
- pharmaceutical composition
- preparation
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700008462 cetrorelix Proteins 0.000 title claims abstract description 81
- 229960003230 cetrorelix Drugs 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 title description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 67
- KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 claims abstract description 46
- 229960001865 cetrorelix acetate Drugs 0.000 claims abstract description 37
- 239000000243 solution Substances 0.000 claims description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 17
- 239000000594 mannitol Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000013065 commercial product Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010068042 Premature ovulation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110113618.9A CN112717119B (zh) | 2021-01-27 | 2021-01-27 | 一种西曲瑞克药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110113618.9A CN112717119B (zh) | 2021-01-27 | 2021-01-27 | 一种西曲瑞克药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112717119A CN112717119A (zh) | 2021-04-30 |
CN112717119B true CN112717119B (zh) | 2024-04-30 |
Family
ID=75594232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110113618.9A Active CN112717119B (zh) | 2021-01-27 | 2021-01-27 | 一种西曲瑞克药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112717119B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611572A2 (de) * | 1993-02-19 | 1994-08-24 | ASTA Medica Aktiengesellschaft | Herstellungsverfahren für Cetrorelix Lyophilisat |
CN102144980A (zh) * | 2011-03-07 | 2011-08-10 | 深圳市健元医药科技有限公司 | 一种更加稳定的lhrh拮抗剂冻干粉针剂 |
WO2015007606A1 (en) * | 2013-07-15 | 2015-01-22 | Bayer Pharma Aktiengesellschaft | Spiroindoline derivatives and pharmaceutical compositions thereof |
CN107007814A (zh) * | 2016-11-04 | 2017-08-04 | 中国科学院昆明动物研究所 | 西曲瑞克在制备治疗艾滋病的药物中的应用 |
-
2021
- 2021-01-27 CN CN202110113618.9A patent/CN112717119B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611572A2 (de) * | 1993-02-19 | 1994-08-24 | ASTA Medica Aktiengesellschaft | Herstellungsverfahren für Cetrorelix Lyophilisat |
CN102144980A (zh) * | 2011-03-07 | 2011-08-10 | 深圳市健元医药科技有限公司 | 一种更加稳定的lhrh拮抗剂冻干粉针剂 |
WO2015007606A1 (en) * | 2013-07-15 | 2015-01-22 | Bayer Pharma Aktiengesellschaft | Spiroindoline derivatives and pharmaceutical compositions thereof |
CN107007814A (zh) * | 2016-11-04 | 2017-08-04 | 中国科学院昆明动物研究所 | 西曲瑞克在制备治疗艾滋病的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112717119A (zh) | 2021-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2428870C (en) | Freeze-dried pantoprazole preparation and pantoprazole injection | |
EP0089245A2 (en) | A stable interferon beta composition and a method of stabilizing interferon beta | |
CN105434373B (zh) | 一种注射用奥拉西坦冻干制剂及其制备方法 | |
AU738413B2 (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
EP0143478A1 (en) | Stable, aqueous, acidic solution of cis-platinum, suitable for injection | |
EP3730133A1 (en) | Fudosteine solution preparation for aerosol inhalation, and preparation method therefor | |
JPH10511967A (ja) | エンロフロキサシンの注射用もしくは注入用溶液 | |
CN112717119B (zh) | 一种西曲瑞克药物组合物及其制备方法 | |
CN110464846A (zh) | 一种美洛昔康组合物、制剂及其制备方法与应用 | |
CN108309944B (zh) | 注射用泮托拉唑钠及其制备方法 | |
CN101254174B (zh) | 一种含卡络磺钠的冻干粉针剂及其制备方法 | |
CN111904936A (zh) | 一种法莫替丁冻干粉针剂 | |
EP3708153A1 (en) | Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor | |
CN114159396A (zh) | 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法 | |
CN112807418A (zh) | 一种西曲瑞克制剂及其制备方法 | |
CN103040737B (zh) | 一种含有兰索拉唑化合物的药物组合物及其制备方法 | |
CN114904001A (zh) | 一种含有醋酸沃诺拉赞的药物组合物及其制备方法 | |
CN104107172B (zh) | 西维来司钠注射用冻干粉的制备方法 | |
CN114685581B (zh) | 一种注射用曲克芦丁及其制备工艺 | |
CN109985232A (zh) | 培化西海马肽的药物组合物及其制备方法 | |
CN103040819A (zh) | 一种含有美洛西林钠化合物的药物组合物及其制备方法 | |
CN115429751B (zh) | 一种人重组卵泡刺激素注射剂及其制备方法 | |
CN113197848B (zh) | 一种重酒石酸间羟胺药物组合物及其制备方法 | |
CN1390539A (zh) | 氨甲环酸冻干粉针剂及制备方法 | |
CN117503714A (zh) | 一种注射用盐酸氨溴索冻干粉针及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240326 Address after: A1, 4th Floor, Building 5, No. 199 Wenfang Road, Jiangning District, Nanjing City, Jiangsu Province, 211100 (Jiangning High tech Park) Applicant after: Nanjing lingnuo Biomedical Technology Research Institute Co.,Ltd. Country or region after: China Address before: 211100 A2, 2 / F, building 1, No. 568, longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Applicant before: NANJING KANGZHOU PHARMACEUTICAL TECHNOLOGY CO.,LTD. Country or region before: China |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |